This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help reduce the risk of estrogen receptive positive (ER+) breast cancer, suggests a new study presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Researchers are finding a link between the increased presence of certain bacteria in a gut biome and colon cancer.
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment.
The Weizmann Institute’s Prof. Yardena Samuels, Prof. Eran Segal, and Dr. Ravid Straussman, with partners at MD Anderson Cancer Center, the NCI, and elsewhere, have discovered that the bacteria living inside cancer cells can be harnessed to provoke an immune reaction against the tumor. The work could also help explain findings showing that the microbiome affects the success of immunotherapy.
Physicians and scientists at The University of Kansas Cancer Center are committed to improving lung cancer outcomes in Kansas.